Skip to main content
Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment
Published Web Location
http://europepmc.org/articles/PMC4576403?pdf=renderNo data is associated with this publication.
Abstract
© 2015 Nasrallah et al.Introduction: In the present study, we sought to identify markers in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that distinguish those achieving remission at 6 months following rituximab or
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.